2. Signaling Pathways
  3. Metabolic Enzyme/Protease
    Vitamin D Related/Nuclear Receptor
  4. RAR/RXR
  5. RXRγ Isoform

RXRγ

NR2B3

RXRγ Related Products (10):

Cat. No. Product Name Effect Purity
  • HY-163436
    F44-A13
    		Antagonist
    F44-A13 is an orally active and highly selective farnesoid X receptor (FXR) antagonist with an IC50 value of 1.1 μM. F44-A13 can optimize cholesterol metabolism and reduce its activity by inducing CYP7A1 expression. F44-A13 reduces levels of cholesterol, triglycerides, and low-density lipoprotein cholesterol (LDL-C) in mouse models. F44-A13 can be used in the study of metabolic diseases associated with lipid disorders.
  • HY-120875
    HX600
    		Agonist 99.40%
    HX600 is a synthetic agonist for RXR (Retinoid X Receptor) heterodimer complex. HX600 prevents ischemia-induced neuronal damage. HX600 has orally bioactivity.
  • HY-N10361
    Drupanin
    		Agonist 99.35%
    Drupanin is an orally active and selective AKR1C3 enzyme inhibitor and an RXRα agonist with an EC50 value of 4.8 μM, which is found in green propolis. Drupanin also activates PPARγ moderately. Drupanin induces adipogenesis and elevates aP2 mRNA levels in 3T3-L1 fibroblasts Drupanin has the potential for the research of breast and prostate cancers.
  • HY-114071
    BMS270394
    		Agonist 98.0%
    BMS270394 is a nuclear retinoic acid receptor (RAR-γ) agonist with the EC50 values of 30 nM and 400 nM for humanRAR-γ and RAR-β, respectively.
  • HY-186156
    RARγ antagonist 1
    		Antagonist
    RARγ antagonist 1 (Compound in claim 4, P20) is a RARγ antagonist. RARγ antagonist 1 can be used for the researches of inflammation and immunology.
  • HY-182331
    WCF-598
    		Degrader
    WCF-598 is a RXRγ (Kd: 234.2 nM) PROTAC degrader. WCF-598 induces RXRγ degradation via the ubiquitin-proteasome pathway and binds directly to RXRγ. WCF-598 indirectly induces AR-V7 degradation, impairs the stability of the RXRγ-AR-V7 complex, downregulates AR-V7 levels, and inhibits the transcription of downstream target genes of AR-V7. WCF-598 induces tumor cell apoptosis, inhibits cell proliferation, activates the p53 signaling pathway, and suppresses cell cycle progression. WCF-598 can be used for the research of prostate cancer.
  • HY-U00449A
    AGN 193109 sodium
    		Antagonist
    AGN 193109 sodium is the sodium salt form of AGN 193109 (HY-U00449). AGN 193109 sodium is the pan antagonist for retinoic acid receptor (RAR), with Kd of 2, 2 and 3 nM, for RARα, RARβ and RARγ, respectively. AGN 193109 sodium reverses TTNPB-induced morphology changes and all-trans retinoic acid (tRA)/9-cis RA/13-cis RA-induced proliferation suppression in ECE16-1 cell. AGN 193109 sodium is the antidote for retinoic acidosis, that ameliorates the skin and mucosal toxicity.
  • HY-173159
    BMS-185354
    		Activator
    BMS-185354 is a selective RARγ activator with an EC50 value of 28 nM. BMS-185354 is promising for research of cancers.
  • HY-180182
    RXR agonist 3
    		Agonist
    RXR agonist 3 (Compound 35) is a potent, partial RXR agonist (EC50s: 3, 3, 8 nM for RXRα, RXRβ, RXRγ, respectively). RXR agonist 3 can be used in the research of Alzheimer's disease, multiple sclerosis, and lymphoma.
  • HY-182352
    RXRγ antagonist-1
    		Antagonist
    RXRγ antagonist-1 (HX531 analogue) is an RXRγ antagonist and can be used as a target protein ligand for the synthesis of PROTAC WCF-598 (HY-182331).